挪威全国颈动脉研究:从症状出现到手术时间过长导致额外神经事件
这项挪威全国多中心前瞻性研究纳入368例症状性颈动脉狭窄患者,发现仅61.7%在指数事件后2周内接受颈动脉内膜切除术,等待期间3.3%发生新神经事件,双联抗血小板治疗与等待期新发神经事件风险降低相关。
要点
- 仅61.7%的症状性颈动脉狭窄患者在指数事件后2周内接受手术。
- 等待手术期间3.3%患者发生新神经事件,延迟主要发生在患者层面和医院内。
- 双联抗血小板治疗与等待期新发神经事件风险降低相关(25.0% vs 62.6%,p=.008)。
核心结论
- 挪威全国症状性颈动脉狭窄患者从指数事件到手术的时间过长,延误主要发生在患者层面和医院内,且延误与新发神经事件相关。
- 双联抗血小板治疗与等待手术期间新发神经事件风险降低相关。
研究设计与样本
- 前瞻性全国多中心研究,连续纳入症状性颈动脉狭窄转诊手术患者,挪威全部15个开展CEA的科室参与。
主要发现
- 入院至转诊血管外科中位时间3天,转诊至实际CEA中位时间5天。
- 总体61.7%患者在指数事件后2周内手术。
- 30天死亡和卒中合计发生率为3.8%。
关键数值与推荐
- 等待手术期间发生新神经事件组双联抗血小板治疗比例为25.0%,其他患者为62.6%(p=.008)。
临床怎么用
- 应缩短症状性颈动脉狭窄患者从指数事件到CEA的时间,重点关注患者延误和院内延误环节。
- 等待手术期间可考虑双联抗血小板治疗以降低新发神经事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/BACKGROUND: The objective was to observe for 1 year all patients in Norway operated on for symptomatic carotid stenosis with respect to (i) the time from the index event to surgery and neurological events during this time; (ii) the level in the healthcare system causing delay of surgical treatment; and (iii) the possible relationship between peri-operative use of platelet inhibitors and neurological events while awaiting surgery. METHODS: This was a prospective national multicentre study of a consecutive series of symptomatic patients. Patients were eligible for inclusion when referred for surgery. An index event was defined as the neurological event prompting contact with the healthcare system. All 15 departments in Norway performing carotid endarterectomy (CEA) participated. RESULTS: Three hundred and seventy one patients were eligible for inclusion between 1 April 2014 and 31 March 2015, and 368 patients (99.2%) were included. Fifty-four percent of the patients contacted their general practitioner on the day of the index event. Primary healthcare referred 84.2% of the patients to hospital on the same day as examined. In hospital median time from admission to referral for vascular surgery was 3 days. Median time between referral to the operating unit and actual CEA was 5 days. Overall, 61.7% of the patients were operated on within 2 weeks of the index event. Twelve patients (3.3%) suffered a new neurological event while awaiting surgery. The percentage of patients on dual antiplatelet therapy was lower (25.0%) in this group than among the other patients (62.6%) (p = .008). The combined 30 day mortality and stroke rate was 3.8%. CONCLUSION: This national study with almost complete inclusion and follow-up shows that the delays occur mainly at patient level and in hospital. The delay is associated with new neurological events. Dual antiplatelet therapy is associated with reduced risk of having a new neurological event before surgery.
引用
- Kjørstad KE, Baksaas ST, Bundgaard D, et al. Editor's Choice - The National Norwegian Carotid Study: Time from Symptom Onset to Surgery is too Long, Resulting in Additional Neurological Events. Eur J Vasc Endovasc Surg. 2017. PMID: 28844552. doi:10.1016/j.ejvs.2017.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。